Apoptosis is the process by which a cell stops dividing and growing and instead begins a process that eventually leads to the cell's controlled death without releasing its contents into the surrounding environment. Together with several enzyme-dependent biochemical processes, apoptosis is characterised by variety of distinctive morphological changes in the cell's structure. Apoptosis is a potentially complex process with several signalling pathways. With apoptosis at the forefront of study, scientists are able to create promising treatment approaches that centre on the voluntary death of abnormal cells. Monoclonal antibodies are desirable therapeutic possibilities due to their ability for disease-specific targeting and low toxicity profiles. By causing target cell-specific death or altering anti-apoptotic signalling pathways, monoclonal antibodies alone may make target cells more susceptible to chemotherapeutic or radiotherapeutic treatments, depending on their mode of action. Abeomics has developed cutting-edge technologies that have been used to build precision antibody such as DR4, NOXA, 14-3-3, TRAM, Caspase-3, Catalase, Caspase-1 etc.